Purpose: To characterize global and segmental circumferential systolic strain (CS) measured by cardiac MRI in athletes after SARS-CoV-2 infection. Materials and Methods: This retrospective observational cohort study included 188 soldiers and collegiate athletes referred for cardiac MRI after SARS-CoV-2 infection (C19+) between July 2020 and February 2021 and a control group of 72 soldiers, collegiate, and high school athletes who underwent cardiac MRI from May 2019 to February 2020, prior to the first SARS-CoV-2 case detected in our region (C19-). Global and segmental CS were measured by feature tracking, then compared between each group using unadjusted and multivariable- adjusted models. Acute myocarditis was diagnosed according to the modified Lake Louise criteria and the location of pathologic late gadolinium enhancement (LGE) was ascertained. Results: Among the 188 C19+ athletes (median age, 25 years [IQR, 23-30]; 131 men), the majority had mild illness. Global CS significantly differed between C19+ and C19- groups, with a median of -24.0 (IQR -25.8, -21.4) versus. -25.0 (-28.0, -22.4), respectively (p = .009). This difference in CS persisted following adjustment for age, sex, body mass index, heart rate, and systolic blood pressure β coefficient 1.29 [95% CI: 0.20, 2.38], p = .02). In segmental analysis, the basal- and mid- inferoseptal, septal and inferolateral segments were significantly different (p < .05), which had a higher frequency of post-COVID late gadolinium enhancement. The global and segmental differences were similar after exclusion of athletes with myocarditis. Conclusion: Among athletes, SARS-CoV-2 infection was associated with a small but statistically significant reduced CS.
Purpose: To characterize global and segmental circumferential systolic strain (CS) measured by cardiac MRI in athletes after SARS-CoV-2 infection. Materials and Methods: This retrospective observational cohort study included 188 soldiers and collegiate athletes referred for cardiac MRI after SARS-CoV-2 infection (C19+) between July 2020 and February 2021 and a control group of 72 soldiers, collegiate, and high school athletes who underwent cardiac MRI from May 2019 to February 2020, prior to the first SARS-CoV-2 case detected in our region (C19-). Global and segmental CS were measured by feature tracking, then compared between each group using unadjusted and multivariable- adjusted models. Acute myocarditis was diagnosed according to the modified Lake Louise criteria and the location of pathologic late gadolinium enhancement (LGE) was ascertained. Results: Among the 188 C19+ athletes (median age, 25 years [IQR, 23-30]; 131 men), the majority had mild illness. Global CS significantly differed between C19+ and C19- groups, with a median of -24.0 (IQR -25.8, -21.4) versus. -25.0 (-28.0, -22.4), respectively (p = .009). This difference in CS persisted following adjustment for age, sex, body mass index, heart rate, and systolic blood pressure β coefficient 1.29 [95% CI: 0.20, 2.38], p = .02). In segmental analysis, the basal- and mid- inferoseptal, septal and inferolateral segments were significantly different (p < .05), which had a higher frequency of post-COVID late gadolinium enhancement. The global and segmental differences were similar after exclusion of athletes with myocarditis. Conclusion: Among athletes, SARS-CoV-2 infection was associated with a small but statistically significant reduced CS.
Athletes with prior SARS-CoV-2 infection had reduced circumferential strain (CS)
on cardiac MRI compared with athletic controls.■ Mild SARS-CoV-2 infection in athletes is associated with reduced
(less negative) global circumferential strain measured by cardiac MRI
(β coefficient 1.29 [95% CI: 0.20, 2.38], p = .02).■ Strain differences were significantly different in the basal-
and mid- inferoseptal, septal, and inferolateral segments (q <
.05 for each), which had a higher frequency of post-COVID late
gadolinium enhancement.
INTRODUCTION
Infection with the SARS-CoV-2 virus is known to cause a wide range of symptoms
spanning from asymptomatic infection to severe respiratory illnesses, acute
respiratory distress syndrome, and death. Similarly, cardiovascular involvement
associated with SARS-CoV-2 has been shown to be highly variable–ranging from
radiographic changes in patients with mild respiratory disease without specific
cardiac complaints (1) to acute fulminant
myocarditis (2, 3). Cardiac MRI has been used to indicate evidence of direct myocardial
injury in patients with COVID-19 with abnormal multiparametric (T1, T2, and
extracellular volume [ECV]) mapping and late gadolinium enhancement (LGE) suggesting
myocardial edema, inflammation and fibrosis (1), consistent with acute myocarditis. Due to the high prevalence of
myocardial inflammation by cardiac MRI shown in an initial series of patients
diagnosed with SARS-CoV- 2 (1) and evidence of
myocarditis as a known cause of sudden cardiac death in competitive athletes (4, 5),
there has been great interest in the development of appropriate screening algorithms
for collegiate and professional athletes who have recovered from this infection
(6, 7). Suggested algorithms include electrocardiography (ECG), high
sensitivity cardiac troponin (TnI) assay, echocardiography, and cardiac MRI. While
initial reports suggested myocarditis rates as high as 15%, subsequent studies in
collegiate athletes recovering from SARS-CoV-2 (8, 9), including from our
institution (10), suggest a lower incidence
in the range of 1.5-3%.Strain imaging detects subclinical myocardial dysfunction and has been shown to
improve the prognostic value of cardiac MRI in acute myocarditis (11, 12).
The objective of this follow-up study was to characterize global and segmental
circumferential systolic strain (CS) in highly trained athletes, including
competitive collegiate athletes and active-duty military soldiers.
METHODS
Study Design and Patients
A retrospective observational cohort study was performed that included 188
athletes (active duty military soldiers and collegiate athletes) with prior
SARS-CoV-2 infection (C19+) who were referred for cardiac MRI examination from a
single institution between July 2020 and February 2021 and a control group
(C19-) consisting of 72 healthy soldiers and high school or collegiate athletes.
The collegiate athletes with SARS-CoV-2 underwent mandatory universal cardiac
screening comprised of TnI measurement, ECG, echocardiography, and cardiac MRI.
The control group underwent cardiac MRI if deemed clinically appropriate by a
provider not involved in this study. The C19- group was retrospectively
identified from patients who underwent cardiac testing for low acuity symptoms
in the presence of strenuous training at our institution from May 2019 to
February 2020, prior to the first case of SARS-CoV-2 reported locally. Control
patients were included if no evidence of myocardial pathology were found. All
athletes participated in > 6 hours of endurance activity per week by
self-report or retrospective confirmation. Punctate LGE in the inferoseptal
right ventricular (RV) insertion point was not considered to be pathological, as
it has been previously observed in athletes (10, 13). Demographics and
cardiac MRI volumetrics of a subset of both C19- (n = 60) and C19+ (n = 59)
athletes has previously been reported, but circumferential strain in these
patients is reported only in this study (10, 14). The study was
approved by the institutional review board with a waiver of consent for
retrospective enrollment.
Cardiac MRI Protocol
A comprehensive cardiac MRI with contrast was performed on a 1.5 Tesla Siemens
Avanto Fit scanner (Siemens Healthcare Sector, Erlangen, Germany). The cardiac
MRI protocol consisted of cine cardiac MRI balanced steady-state free precession
imaging to calculate left and right ventricular volumes, left ventricular
ejection fraction (LVEF), and myocardial mass. Intravenous gadolinium contrast
(gadobutrol, Gadavist, Bayer Healthcare Pharmaceuticals, Wayne, NJ, USA at a
dose of 0.15 mmol/kg) was administered through a peripheral intravenous line.
LGE was performed using segmented inversion recovery (optimized inversion time
to null myocardium) and single shot phase sensitive inversion recovery
(inversion time of 300ms) imaging in standard long-axis planes and a short-axis
stack. Native T1 mapping, T2 mapping, and post- contrast (15 minutes after
contrast administration) T1 mapping was performed. T1 mapping was performed
using a modified Look-Locker inversion recovery sequence acquired using a 5(3s)3
protocol before contrast and 4(1)3(1)2 protocol after contrast.
Cardiac MRI Postprocessing
Cardiac MRI post-processing was performed using Medis Suite MR 2.1 (Medis,
Leiden, The Netherlands). CS was calculated by feature tracking (FT) using Medis
QStrain from each of the 16 short-axis myocardial segments, following the
standard model as proposed by the American Heart Association (15), excluding the apical segment. Strain
analysis was performed by a single reader (K G.-D.), who has 4 years of
experience analyzing strain and was blinded to SARS-CoV-2 status. Strain
measurements were repeated in a subset of 20 patients more than 6 months from
initial analysis by the same user to assess for intra-observer variability; a
second user (J.S.) repeated analysis of those 20 patients to assess for
inter-observer variability. Assessment of presence or absence of LGE, as well as
its location within the 17-segment model, was done by two cardiologists (S.H.
and J.D.) each with over 10 years of experience reading cardiac MRI. If there
were disagreements, a third cardiologist (D.C.) repeated assessment of LGE.
Acute myocarditis was diagnosed according to the modified Lake Louise Criteria
(LLC) (16).
Statistical Analysis
Summary statistics were calculated as counts (percentages) or median
(interquartile range [IQR]). Between group unadjusted comparisons were made with
the chi-squared and Wilcoxon rank-sum tests. All tests were 2-sided, and
p<.05 was considered statistically significant. The association between
LV mass index (LVMi), RV ejection fraction (RVEF), and RV volume index with
average global CS were examined in linear regression models that included prior
COVID-19 infection status and adjustment for age, sex, body mass index (BMI),
heart rate (HR), and systolic blood pressure (SBP). Among C19+ athletes, the
associations between T1, T2, and ECV with CS were also examined in a
multivariable-adjusted linear regression. Prior to entry to regression models,
the distributions of dependent variables were examined, then log transformed, as
appropriate, with normality of residuals tested post regression. When
appropriate, multiple comparison correction was performed in a two-stage step-up
method of Benjamini, Krieger, and Yekutieli with a false discovery rate of 5%.
Inter- and intra-observer variability were calculated using an intraclass
coefficient. Statistical analysis was performed using Prism 9 (GraphPad
Software, LLC, San Diego, CA, USA).
RESULTS
Study Patient Characteristics
Our cohort included 72 patients in the C19- group and 188 in the C19+ group
(). The
median age was 25 years (IQR, 23-30) and 21 years (IQR, 20-22) in the C19- and
C19+ groups, respectively (p<0.001). Both groups were majority men,
though there were more males in the C19- group (C19+: 131 (70%), C19-: 64 (89%),
p<.001). Self-reported race and ethnicity proportions were similar
between groups. Height, weight, body surface area, HR, SBP, and diastolic blood
pressure were also similar between the two groups.Patient Demographics
C19+ Athlete Characteristics
The median time from COVID-19 diagnosis to cardiac MRI examination was 30 days
(IQR, 15–56). Of the 188 C19+ athletes, the vast majority had mild
illnesses and recovered at home; only 5 (3%) required hospitalization, of which
2 (1%) needed intensive care unit-level care, though none were mechanically
ventilated. Five C19+ patients (2%) had abnormal TnI (defined as >0.03
ng/mL), 28 (15%) had borderline abnormal ECG as interpreted by a sports
cardiologist, and 15 (8%) had an abnormal echocardiogram. Ten (5%) C19+ athletes
were diagnosed with acute myocarditis according to the modified LLC (16) using our established normative values
for T1 and T2 parametric mapping, as none had an abnormal TnI, ECG, or
echocardiogram; none of these athletes were hospitalized.
Cardiac MRI Volumetric, Functional, and Parametric Mapping
Comparisons
Cardiac volumes, function, and parametric mapping were compared among groups
(). C19+
athletes had similar LV volumes and function, but higher LV mass and RV volumes,
and reduced RV ejection fraction compared with the C19- group (RVEF, 51% vs 53%,
p < .001). After adjusting for age, sex, BMI, HR and SBP, prior COVID-19
infection independently associated with significantly higher log transformed LV
mass index (β coefficient, 0.052 [95% CI: 0.030, 0.074]; p <
.001), lower log transformed RVEF (β coefficient, -0.020 [-0.032,
-0.008]; p = .001, and higher log transformed RV end systolic index (β
coefficient, 0.035 [0.004, 0.065]; p = .02). On parametric mapping, there was no
evidence of differences between groups for native T1 relaxation time, T2, or
ECV.Cardiac MRI Volumetrics and Parametric Mapping
Global Circumferential Strain
Compared with the C19- group, C19+ athletes had higher (less negative) global CS
(median, -24.0 vs -25.0; p=.009), as well as CS of the basal (-23.4 vs –
24.5, p=.03 and mid-left ventricular sections (-20.3 vs -22.3, p<.001;
,
). This
finding persisted even after exclusion of individuals with myocarditis
(). Prior
infection remained independently associated with reduced global CS (β
coefficient, 1.29 (95% CI: 0.20, 2.38], p = .02) in multivariable regression
adjusted for age, sex, BMI, HR, and SBP. Moreover, this effect persisted with
further adjustment for LVMi, which was higher in the C19+ group, to the
multivariable model (1.32 [0.19, 2.5]; p = .02). In a separate multivariable
regression analysis with the addition of parametric mapping data to the above
clinical variables, within just the C19+ cohort, CS in the basal or mid section
was not significantly associated with T1 relaxation time, T2, or ECV in the
respective LV section. Inter- and intra-observer variability analysis performed
on a subset of the patients showed strong correlation for global CS as well as
for CS at each of the sections (Table
S2).
Table S2.
Inter-observer and Intra-observer Variability
Circumferential Strain ComparisonGlobal circumferential strain comparison. Average global circumferential
strain and from each section in athletic controls (C19-) and athletes
after SARS-CoV-2 infection (C19+) are shown with dashed lines
representing median and IQR. * p < .05 and
** p < .01 when compared by Wilcoxon rank-sum
test.
Segmental Circumferential Strain
After correcting for multiple comparisons, segmental CS was found to be higher
(less negative) in the basal- to-mid-inferoseptal, mid-anteroseptal,
mid-inferior, and mid-inferolateral segments in unadjusted analysis comparing
C19+ with C19- athletes (q<0.05 for each, , ). A similar difference was observed when
comparing C19- to C19+ athletes without myocarditis (). Pathologic LGE in
C19+ athletes with myocarditis (n = 10) was most frequently located in the
basal- and mid-inferoseptum, mid-inferior, and mid-inferolateral segments
(), in a
similar pattern to the abnormal segmental CS findings.Segmental Circumferential Strain ComparisonLocation of circumferential strain differences and pathologic LGE within
the 17-segment model. (A-B) Segmental circumferential strain difference
(95% CI) between athletes after SARS-CoV-2 (C19+) and athletic controls
(C19-), * q < .05 and ** q < .01 when
compared using the Wilcoxon rank-sum test followed by multiple
comparison correction in a two-stage step-up method of Benjamini,
Krieger, and Yekutieli with a false discovery rate of 5%. C) Frequency
of the location of pathologic late gadolinium enhancement (LGE) in C19+
athletes diagnosed with myocarditis.
DISCUSSION
This study aimed to compare global and segmental CS measured by cardiac MRI in
athletes after SARS- CoV-2 infection and athletic controls. SARS-CoV-2 positivity
was associated with lower global (β coefficient, 1.29 [95% CI: 0.20, 2.38], p
= .02) and segmental CS. Segmental analyses showed that COVID- 19 had a predilection
for the basal-mid inferior myocardial segments, with strain abnormalities and LGE
localized to these regions, for which COVID-19 has previously been shown to have a
predilection for (17).Strain analysis by FT has been shown to improve cardiac MRI diagnostic accuracy of
acute myocarditis, especially when the LVEF is preserved (18-21), although
abnormal strain is not currently incorporated as part of the LLC (16). The location and extent of LGE is strongly
predictive of future major adverse cardiac events (MACE) post-myocarditis in
patients with preserved LVEF (22, 23). More recently, studies have shown that
strain quantified by FT MRI is an independent prognosticator of long-term MACE and
LV functional recovery after myocarditis in both preserved and reduced EF (11, 12).
In acute myocarditis, global CS has been shown to correlate with T1 and T2
relaxation times, indicative of myocardial edema and inflammation, as well as
extracellular matrix expansion (20). Segments
with visually identifiable LGE or edema had reduced CS (20).In our study, athletes with prior SARS-CoV-2 infection had significantly worse global
and segmental CS compared with athletic controls. This difference was observed even
among C19+ athletes without cardiac MRI evidence of myocarditis. While the absolute
difference in strain was small (-1.0 difference between C19+ and C19- group), this
represents a relative reduction of 4% of global CS. By comparison, a relative
reduction of 12% in global longitudinal strain has been used as the cutoff for
evidence of chemo-induced cardiotoxicity, and initiation of cardioprotective therapy
using strain-guided management has been shown to be superior to EF-guided management
(24). Furthermore, a -1.0 absolute
difference in strain by cardiac MRI is associated with a 21% increased risk of MACE
after myocarditis, independent of other traditional features of cardiac MRI such as
LVEF or LGE extent (11). Longitudinal outcome
studies are necessary to fully understand the clinical significance of these
findings, which will provide better understanding of myocardial changes
post-COVID.Reduction in global strain parameters and increased ECV in the absence of formal
criteria for myocarditis was reported in a study of 40 patients who recovered from
moderate or severe SARS-CoV-2 infection (25).
These findings suggest that viral involvement of SARS-CoV-2 in the myocardium may
occur at a nominal level, resulting in a subclinical change in myocardial function,
and that cardiac MRI with strain is a sensitive method for studying post-SARS-CoV-2
cardiac sequelae. In an exploratory analysis, CS was not associated with T1, T2, or
ECV within the C19+ group after adjusting for clinical variables (age, sex, HR, BMI,
and BP). While speculative, the worse systolic strain observed in C19+ athletes may
suggest a relatively greater effect of SARS-CoV-2 on cardiomyocyte function compared
to the interstitial space. Of note, direct infection of SARS-CoV-2 in cardiomyocytes
has been demonstrated in vitro through an angiotensin converting
enzyme 2 dependent pathway, resulting in increased cell size and decreased
contraction (26, 27). However, further investigation into the clinical
significance of these strain differences in the absence of visible LGE is
needed.The diagnosis of myocarditis in athletes post SARS-CoV-2 presents a unique challenge
as intensive athletic training can lead to adaptive changes that must not be
confounded with pathology (28). In our study,
none of the athletes diagnosed with myocarditis had an abnormal TnI, ECG, or
echocardiogram, although testing was done in the convalescent period after the acute
infectious period had resolved. Furthermore, mostpatients diagnosed with SARS-CoV-2
had relatively mild infections with nonspecific symptoms that may overlap with those
of myocarditis, thus requiring a higher index of suspicion to pursue further
testing.Our study included athletes undergoing mandatory cardiac MRI post SARS-CoV-2 as part
of return-to-play for collegiate athletes and clinically-indicated cardiac MRI for
tactical military soldiers, who both had a similar rate (5%) of myocarditis,
consistent with prior studies in athletic populations (8, 9). This contrasts with
previous studies that reported a much higher incidence of myocarditis in post
SARS-CoV-2 patients who were older with more comorbidities (1), had more severe illnesses, and were not competitive athletes
(29). By comparison, a study of a
return-to-play screening algorithm without universal cardiac MRI in professional
athletes reported a much lower incidence of myocarditis (30), and a large, multicenter collegiate athlete cohort in
which only 7% underwent cardiac MRI similarly found low rates of myocarditis (31).Cardiac remodeling is known to occur in competitive athletes (31) with both volumetric and parametric mapping changes; thus,
an athletic control group is critical to detect true pathologic differences. Like
prior studies, our data demonstrated increased RV volumes and decreased RVEF
compared with athletic controls, though the median values remained in the normal
range (1, 29). Whether these differences result from direct myocardial effects of
SARS-CoV-2 or secondary effects from residual pulmonary abnormalities is unclear.
Our data also demonstrate significantly increased indexed LV mass after SARS-CoV-2,
but no evidence of differences in LV volumes or function.There are inherent limitations of our retrospective observational study design with
limited follow-up due to study of an emerging post-viral syndrome from the
SARS-CoV-2 pandemic. Despite multivariable- adjustment, residual confounding may
exist. Race and ethnicity were self-reported, and the majority of patients in the
C19- group and approximately half of the C19+ athletes chose not to report these
demographics. Since athletic participation was self-reported, there could be
difference in athletic conditioning between C19+ and C19- groups, which could
contribute to differences in volumetrics, LVMi, and CS. Lastly, cardiac MRI was
obtained in the C19- group for various clinical indications; thus, the control
athletes did not undergo a standardized protocol that required parametric mapping,
and as such, T1, T2, and ECV data were not available for some patients. Due to the
missing data, multivariable analysis to account for effects of T1 relaxation time,
T2 relaxation time, or ECV on global CS was only performed within the C19+
cohort.In conclusion, differences in myocardial systolic strain exist in athletes with prior
SARS-CoV-2 infection compared with athletes without prior infection, independent of
demographics, hemodynamic parameters, and LV mass. Reduced myocardial strain
co-localized to segments shown to be most likely affected by SARS-CoV-2 infection,
even in the absence of detectable myocardial inflammation or LGE. Further study is
necessary to determine the clinical significance of this small but statistically
significant worsening of myocardial strain.
Table 1.
Patient Demographics
Table 2.
Cardiac MRI Volumetrics and Parametric Mapping
Table 3.
Circumferential Strain Comparison
Table 4.
Segmental Circumferential Strain Comparison
Table S1.
Circumferential Strain Comparing Athletic Controls and C19+ Athletes
Not Diagnosed With Myocarditis.
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: Saurabh Rajpal; Matthew S Tong; James Borchers; Karolina M Zareba; Timothy P Obarski; Orlando P Simonetti; Curt J Daniels Journal: JAMA Cardiol Date: 2021-01-01 Impact factor: 14.676
Authors: Kady Fischer; Sarah J Obrist; Sophie A Erne; Anselm W Stark; Maximilian Marggraf; Kyoichi Kaneko; Dominik P Guensch; Adrian T Huber; Simon Greulich; Ayaz Aghayev; Michael Steigner; Ron Blankstein; Raymond Y Kwong; Christoph Gräni Journal: JACC Cardiovasc Imaging Date: 2020-07-15
Authors: Matthew W Martinez; Andrew M Tucker; O Josh Bloom; Gary Green; John P DiFiori; Gary Solomon; Dermot Phelan; Jonathan H Kim; Willem Meeuwisse; Allen K Sills; Dana Rowe; Isaac I Bogoch; Paul T Smith; Aaron L Baggish; Margot Putukian; David J Engel Journal: JAMA Cardiol Date: 2021-07-01 Impact factor: 14.676
Authors: Daniel E Clark; Amar Parikh; Jeffrey M Dendy; Alex B Diamond; Kristen George-Durrett; Frank A Fish; James C Slaughter; Warne Fitch; Sean G Hughes; Jonathan H Soslow Journal: Circulation Date: 2020-12-17 Impact factor: 29.690
Authors: Dan Leslie Li; Giovanni Davogustto; Jonathan Harvey Soslow; Jean Wang Wassenaar; Amar Pradip Parikh; Joshua David Chew; Jeffrey Michael Dendy; Kristen Marie George-Durrett; David Andres Parra; Daniel Eugene Clark; Sean Gillette Hughes Journal: Am J Cardiol Date: 2022-01-19 Impact factor: 2.778